Format

Send to

Choose Destination
Expert Opin Biol Ther. 2019 May;19(5):433-442. doi: 10.1080/14712598.2019.1594770. Epub 2019 Apr 8.

Acute blood pressure elevation associated with biological therapies for cancer: a focus on VEGF signaling pathway inhibitors.

Author information

1
a Department of Medicine , University of Perugia , Perugia , Italy.
2
b Unit of Internal Medicine , Terni University Hospital , Terni , Italy.
3
c Department of Medical Sciences - Hypertension Center , University of Torino - AOU Città della Salute e della Scienza di Torino , Torino , Italy.
4
d Department of Clinical and Experimental Sciences , University of Brescia , Brescia , Italy.

Abstract

Treatment with biological agents interfering with mechanisms of angiogenesis, such as vascular endothelial growth factor (VEGF) signaling pathway (VSP) inhibitors, was associated with an enhanced risk of acute and severe blood pressure (BP) increase and development of hypertensive emergencies. Areas covered: The present article will review the scientific literature reporting hypertensive emergencies as a complication of biological treatment with VSP inhibitors. Hypertensive emergency is a life-threatening condition characterized by very high BP values (>180/110 mmHg) associated with acute organ damage. The exact mechanism of action is still incompletely clarified. Endothelial dysfunction following reduced bioavailability of nitric oxide has been hypothesized to play an important role in promoting hypertension and the occurrence of acute organ damage. Expert opinion: Prevention, prompt recognition and treatment of hypertensive emergencies associated with treatment with VSP-inhibitors are essential to reduce the risk of adverse events. Not infrequently, the occurrence of hypertensive emergency led to VSP treatment discontinuation, with potential negative consequences on patient overall survival. The present review aims at providing detailed knowledge for the clinician regarding this specific issue, which could be of high impact in usual clinical practice, given the increasing burden of indications to treatment with biological agents targeted to the VEGF pathway.

KEYWORDS:

Arterial hypertension; angiogenesis inhibitors; anti VEGF drugs; cancer therapies; endothelial cells; hypertensive emergencies

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center